HCPCS codes for knee injection
This article was originally published in The Gray Sheet
Executive Summary
CMS heard feedback from manufacturers of hyaluronic acid-based osteoarthritis knee treatments at a public HCPCS coding and payment meeting May 11. A preliminary decision from the agency found that five such products on the market show "no significant therapeutic distinctions," leading the agency to propose that they all be grouped under a single code. CMS also solicited comments on maintaining the current system by which the products fall under two codes - one for chemically altered hyaluronan and one for natural hyaluronate products. Attorney Paul Radensky, MD, who presented on behalf of Sanofi-Aventis (Hyalgan), argued for the second year that each product should be given its own code based on molecular weight (1"The Gray Sheet" June 20, 2005, p. 3). Hyalgan competes with Genzyme's Synvisc, Smith & Nephew's Supartz, Johnson & Johnson/Ortho Biotech's Orthovisc and Ferring Pharmaceuticals' Euflexxa. The agency will make a final coding determination in November...
You may also be interested in...
Osteoarthritis Knee-Treatment Device Firms Clash Over Physician Fees
Genzyme is urging CMS to retain a single HCPCS procedure billing code for the three hyaluronic acid-based devices competing with its Synvisc
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.